PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
27838885-2	2017	Here, we investigated a 25-year-old patient with multiple PHEOs associated with a non-sense germline MAX mutation.	pheos	58-63	MYC associated factor X	Homo sapiens	101-104
31278686-4	2019	RESULTS: All MTCs and PHEOs were positive for RET9 and RET51.	pheos	22-27	ret proto-oncogene	Homo sapiens	55-60
31278686-15	2019	RET9 was more highly expressed than RET51 in PHEOs.	pheos	45-50	ret proto-oncogene	Homo sapiens	36-41
29534198-10	2018	Conclusions: MAX-related PHEOs exhibit a marked 18F-FDOPA uptake, a finding that illustrates the common well-differentiated chromaffin pattern of PHEOs associated with activation of kinase signaling pathways.	pheos	25-30	MYC associated factor X	Homo sapiens	13-16
29534198-10	2018	Conclusions: MAX-related PHEOs exhibit a marked 18F-FDOPA uptake, a finding that illustrates the common well-differentiated chromaffin pattern of PHEOs associated with activation of kinase signaling pathways.	pheos	146-151	MYC associated factor X	Homo sapiens	13-16
27838885-4	2017	In addition, both adrenal glands were found to have diffuse or nodular adrenal medullary hyperplasia (AMH), a histopathological feature previously described as a precursor of MEN2- and SDHB-related PHEOs but not MAX.	pheos	198-203	succinate dehydrogenase complex iron sulfur subunit B	Homo sapiens	185-189
25873086-4	2015	EXPERIMENTAL DESIGN: [(68)Ga]-DOTATATE PET/CT was prospectively performed in 17 patients with SDHB-related metastatic PHEOs/PGLs.	pheos	118-123	succinate dehydrogenase complex iron sulfur subunit B	Homo sapiens	94-98
26523625-14	2016	CONCLUSION: In children, metastatic PHEOs/PGLs are mainly due to SDHB mutations; in adults they are equally distributed between in SDHB mutations and AST, with better 5- and 10-year survival rates for ASTs.	pheos	36-41	succinate dehydrogenase complex iron sulfur subunit B	Homo sapiens	65-69
24846270-3	2014	The MAPK pathway plays a role in numerous aggressive tumors and has been associated with a subgroup of PHEOs/PGLs, including K-RAS-, RET-, and NF1-mutated tumors.	pheos	103-108	mitogen-activated protein kinase 1	Mus musculus	4-8
25048685-3	2014	This study evaluated the size and age at diagnosis of primary SDHB-related PHEOs/PGLs as independent predictors of their metastatic behavior and outcome (survival).	pheos	75-80	succinate dehydrogenase complex iron sulfur subunit B	Homo sapiens	62-66
24846270-3	2014	The MAPK pathway plays a role in numerous aggressive tumors and has been associated with a subgroup of PHEOs/PGLs, including K-RAS-, RET-, and NF1-mutated tumors.	pheos	103-108	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	125-130
24846270-3	2014	The MAPK pathway plays a role in numerous aggressive tumors and has been associated with a subgroup of PHEOs/PGLs, including K-RAS-, RET-, and NF1-mutated tumors.	pheos	103-108	ret proto-oncogene	Mus musculus	133-136
24846270-3	2014	The MAPK pathway plays a role in numerous aggressive tumors and has been associated with a subgroup of PHEOs/PGLs, including K-RAS-, RET-, and NF1-mutated tumors.	pheos	103-108	neurofibromin 1	Mus musculus	143-146
24846270-4	2014	Our aim was to establish whether MAPK signaling may also play a role in aggressive, succinate dehydrogenase (SDH) B mutation-derived PHEOs/PGLs.	pheos	133-138	mitogen-activated protein kinase 1	Mus musculus	33-37
24846270-4	2014	Our aim was to establish whether MAPK signaling may also play a role in aggressive, succinate dehydrogenase (SDH) B mutation-derived PHEOs/PGLs.	pheos	133-138	aminoadipate-semialdehyde synthase	Mus musculus	84-107
24846270-4	2014	Our aim was to establish whether MAPK signaling may also play a role in aggressive, succinate dehydrogenase (SDH) B mutation-derived PHEOs/PGLs.	pheos	133-138	aminoadipate-semialdehyde synthase	Mus musculus	109-112
24846270-5	2014	Expression profiling and western blot analysis indicated that specific aspects of MAPK-signaling are active in SDHB PHEOs/PGLs, suggesting that inhibition by statin treatment could be beneficial.	pheos	116-121	mitogen-activated protein kinase 1	Mus musculus	82-86
24846270-5	2014	Expression profiling and western blot analysis indicated that specific aspects of MAPK-signaling are active in SDHB PHEOs/PGLs, suggesting that inhibition by statin treatment could be beneficial.	pheos	116-121	succinate dehydrogenase complex, subunit B, iron sulfur (Ip)	Mus musculus	111-115
23873112-6	2013	Positive staining for HSP90 was found in 14 of 17 malignant (82.35%) and in 5 of 21 (23.81%) benign PHEOs.	pheos	100-105	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	22-27
23322515-3	2013	In particular, malignant PHEOs/PGLs, more specifically the tumors that result from mutations in succinate dehydrogenase subunit B (SDHB), are a clear concern, and novel therapies should be developed to address this problem.	pheos	25-30	succinate dehydrogenase complex iron sulfur subunit B	Homo sapiens	96-129
23481210-8	2013	New discoveries related to the role of the HIF-1/HIF-2alpha genes in the pathogenesis of almost all inherited PHEOs/PGLs may call for a new regrouping of these tumors and discoveries of new treatment targets.	pheos	110-115	hypoxia inducible factor 1 subunit alpha	Homo sapiens	43-48
23481210-8	2013	New discoveries related to the role of the HIF-1/HIF-2alpha genes in the pathogenesis of almost all inherited PHEOs/PGLs may call for a new regrouping of these tumors and discoveries of new treatment targets.	pheos	110-115	endothelial PAS domain protein 1	Homo sapiens	49-59
23539726-12	2013	CONCLUSION: This case represents the first association of a somatic HIF2A gain-of-function mutation with PHEO and congenital polycythemia, and it alerts physicians to perform proper genetic screening in patients presenting with multiple norepinephrine-producing PHEOs and polycythemia.	pheos	262-267	endothelial PAS domain protein 1	Homo sapiens	68-73
23322515-3	2013	In particular, malignant PHEOs/PGLs, more specifically the tumors that result from mutations in succinate dehydrogenase subunit B (SDHB), are a clear concern, and novel therapies should be developed to address this problem.	pheos	25-30	succinate dehydrogenase complex iron sulfur subunit B	Homo sapiens	131-135
12375051-5	2002	We, therefore, used a double differential polymerase chain reaction (ddPCR) for determination of the amplification/deletion profiles of erbB-1, -2, -3 and -4 genes in formalin-fixed, paraffin embedded (FFPE) specimens of human PHEOs.	pheos	227-232	epidermal growth factor receptor	Homo sapiens	136-157
22859959-3	2012	To date, the molecular mechanisms causing the more aggressive phenotype in SDHB-PHEOs/PGLs remain largely unknown.	pheos	80-85	succinate dehydrogenase complex iron sulfur subunit B	Homo sapiens	75-79
22859959-10	2012	Although there was no direct evidence for increased reactive oxygen species production, elevated superoxide dismutase 2 expression may reflect elevated oxidative stress in SDHB-derived PHEOs/PGLs.	pheos	185-190	succinate dehydrogenase complex iron sulfur subunit B	Homo sapiens	172-176
22859959-12	2012	In addition, we present evidence for increased LDHA and SOD2 expression in SDHB-PHEOs/PGLs, proteins that have been proposed as promising therapeutic targets in other cancers.	pheos	80-85	lactate dehydrogenase A	Homo sapiens	47-51
22859959-12	2012	In addition, we present evidence for increased LDHA and SOD2 expression in SDHB-PHEOs/PGLs, proteins that have been proposed as promising therapeutic targets in other cancers.	pheos	80-85	superoxide dismutase 2	Homo sapiens	56-60
22859959-12	2012	In addition, we present evidence for increased LDHA and SOD2 expression in SDHB-PHEOs/PGLs, proteins that have been proposed as promising therapeutic targets in other cancers.	pheos	80-85	succinate dehydrogenase complex iron sulfur subunit B	Homo sapiens	75-79
19570738-9	2009	The so called "flip-flop" imaging showing superiority of non-specific [18F] flurodeoxyglucose (FDG) PET over specific [18F]DA PET has been described in rapidly progressive, often metastatic SDHB-associated PHEOs.	pheos	206-211	succinate dehydrogenase complex iron sulfur subunit B	Homo sapiens	190-194